AC
ALNY icon

Alexandria Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Alexandria Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$23.1M Sell
122,216
-3,473
-3% -$651K 2.14% 4
2021
Q2 		$21.3M Sell
125,689
-1,742
-1% -$255K 1.98% 4
2021
Q1 		$18M Sell
127,431
-867
-0.7% -$130K 1.82% 7
2020
Q4 		$16.7M Sell
128,298
-2,436
-2% -$325K 1.77% 6
2020
Q3 		$18.6M Sell
130,734
-1,083
-0.8% -$154K 2.22% 4
2020
Q2 		$19.5M Sell
131,817
-10,637
-7% -$1.43M 2.53% 4
2020
Q1 		$15.5M Sell
142,454
-6,983
-5% -$806K 2.54% 4
2019
Q4 		$17.2M Buy
149,437
+739
+0.5% +$73.7K 2.3% 5
2019
Q3 		$12M Buy
148,698
+8,182
+6% +$647K 1.77% 7
2019
Q2 		$10.2M Buy
140,516
+327
+0.2% +$25.1K 1.45% 12
2019
Q1 		$13.1M Sell
140,189
-295
-0.2% -$24.7K 1.9% 6
2018
Q4 		$10.2M Sell
140,484
-342
-0.2% -$26.3K 1.66% 9
2018
Q3 		$12.3M Buy
140,826
+224
+0.2% +$22.5K 1.81% 8
2018
Q2 		$13.8M Sell
140,602
-239
-0.2% -$23.7K 2.08% 7
2018
Q1 		$16.8M Sell
140,841
-5,576
-4% -$719K 2.49% 3
2017
Q4 		$18.6M Buy
+146,417
New +$18.4M 2.71% 3

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alexandria Capital's ALNY Position: Q3 2021 in Review

Alexandria Capital reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.8% in Q3 2021, selling an estimated $651K and leaving 122,216 shares worth $23.1M. The position accounts for 2.14% of the portfolio, ranked #4.

Alexandria Capital first reported a position in ALNY in Q4 2017 and has held it in 16 quarters since. 404 funds tracked by Wall St. Rank hold ALNY as of Q3 2021.

  • Alexandria Capital held 122,216 shares of Alnylam Pharmaceuticals worth $23.1M as of Q3 2021.
  • Alexandria Capital sold 3,473 Alnylam Pharmaceuticals shares in Q3 2021, an estimated $651K.
  • Alnylam Pharmaceuticals made up 2.14% of Alexandria Capital's portfolio in Q3 2021, its #4 holding.
  • Alexandria Capital first reported a position in Alnylam Pharmaceuticals in Q4 2017 and has held it in 16 quarters since.
  • 404 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2021.

Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.